{"classes":[{"categories":[{"measurements":[{"comment":"A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics.","groupId":"OG000","lowerLimit":"11.4","upperLimit":"NA","value":"22.3"},{"comment":"A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics.","groupId":"OG001","lowerLimit":"4.7","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"},{"description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.","id":"OG001","title":"ROS1 Positive Population (Phase 1)"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat (ITT) analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. Here, \"Number Analyzed\" signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Survival (OS) (Phase 1)","type":"SECONDARY","unitOfMeasure":"Months"}